Advanced search
Publication Cover
Cancer Biology & Therapy Volume 19, 2018 - Issue 11
Submit an article Journal homepage
1,636
Views
18
CrossRef citations to date
0
Altmetric
Bedside to Bench Report

CMTR1-ALK: an ALK fusion in a patient with no response to ALK inhibitor crizotinib

Xue DuDepartment of Pathology, Hospital of Chinese PLA, Cancer Center of People’s Liberation Army of China, Beijing, ChinaView further author information
,
Yun ShaoDepartment of Pathology, Hospital of Chinese PLA, Cancer Center of People’s Liberation Army of China, Beijing, ChinaView further author information
,
Hongjun GaoDepartment of Lung Cancer, Hospital of Chinese PLA, Cancer Center of People’s Liberation Army of China, Beijing, ChinaView further author information
,
Xueli ZhangDepartment of Pathology, Hospital of Chinese PLA, Cancer Center of People’s Liberation Army of China, Beijing, ChinaView further author information
,
Han ZhangDepartment of Pathology, Hospital of Chinese PLA, Cancer Center of People’s Liberation Army of China, Beijing, ChinaView further author information
,
Yi BanDepartment of Pathology, Hospital of Chinese PLA, Cancer Center of People’s Liberation Army of China, Beijing, ChinaView further author information
,
Haifeng QinDepartment of Lung Cancer, Hospital of Chinese PLA, Cancer Center of People’s Liberation Army of China, Beijing, ChinaCorrespondence[email protected]
View further author information
&
Yanhong TaiDepartment of Pathology, Hospital of Chinese PLA, Cancer Center of People’s Liberation Army of China, Beijing, ChinaCorrespondence[email protected]
View further author information
 show all
Pages 962-966 | Received 28 Dec 2017, Accepted 20 May 2018, Published online: 01 Oct 2018

Citations (18)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Xingyu Zhu, Yuqi He, Yin Wang, Yan Lei, Xiaoxing Su, Yifan Liu, Shuangxiu Wu & Zhengfu He. (2021) Identification of a Novel SLC8A1-ALK Fusion and Non-Canonical Expression Significantly Responding to ALK-TKIs in Lung Adenocarcinoma: A Case Report. OncoTargets and Therapy 14, pages 4915-4920.
Read now
Chengzhi Cai, Yaling Long, Yanying Li & Meijuan Huang. (2020) Coexisting of COX7A2L–ALK, LINC01210–ALK, ATP13A4–ALK and Acquired SLCO2A1–ALK in a Lung Adenocarcinoma with Rearrangements Loss During the Treatment of Crizotinib and Ceritinib: A Case Report. OncoTargets and Therapy 13, pages 8313-8316.
Read now

Articles from other publishers (16)

Zizong Wang, Yushuai Han, Houquan Tao, Mengxiang Xu, Zhengchuang Liu, Jianhua Zhu, Wei Li, Jie Ma, Zhifang Liu, Weiran Wang & Tonghui Ma. (2022) Molecular characterization of genomic breakpoints of ALK rearrangements in non‐small cell lung cancer . Molecular Oncology 17:5, pages 765-778.
Crossref
Maojing Guan, Jianping Xu & Qingming Shi. (2023) Molecular determinants of clinical outcomes for anaplastic lymphoma kinase–positive non-small cell lung cancer in Chinese patients: A retrospective study. Cancer Genetics 270-271, pages 32-38.
Crossref
Yan Xiang, Shiyu Zhang, Xiaoxu Fang, Yingying Jiang, Tingwen Fang, Jinwen Liu & Kaihua Lu. (2022) Therapeutic Advances of Rare ALK Fusions in Non-Small Cell Lung Cancer. Current Oncology 29:10, pages 7816-7831.
Crossref
Maojing Guan, Jianping Xu & Qingming Shi. (2022) Gene Complexity and Clinical Outcomes of Anaplastic Lymphoma Kinase–Positive Non-Small Cell Lung Cancer in Chinese Patients: A Retrospective Study. SSRN Electronic Journal.
Crossref
Peiyi Xia, Lan Zhang, Pan Li, Enjie Liu, Wencai Li, Jianying Zhang, Hui Li, Xiaoxing Su & Guozhong Jiang. (2021) Molecular characteristics and clinical outcomes of complex ALK rearrangements identified by next-generation sequencing in non-small cell lung cancers. Journal of Translational Medicine 19:1.
Crossref
Xue Pan, Anyuan Zhong, Yufei Xing, Xi Li, Haiwei Du & Minhua Shi. (2021) A novel GHR-ALK fusion gene in a patient with metastatic lung adenocarcinoma and its response to crizotinib: a case report . Journal of International Medical Research 49:9, pages 030006052110446.
Crossref
Huamiao Zhou, Binyue Xu, Jili Xu, Guomeng Zhu & Yong Guo. (2021) Novel MRPS9-ALK Fusion Mutation in a Lung Adenocarcinoma Patient: A Case Report. Frontiers in Oncology 11.
Crossref
Amber Willbanks, Shaun Wood & Jason X. Cheng. (2021) RNA Epigenetics: Fine-Tuning Chromatin Plasticity and Transcriptional Regulation, and the Implications in Human Diseases. Genes 12:5, pages 627.
Crossref
Fabrizio Tabbò, Luisella Righi, Riccardo Taulli & Silvia Novello. 2021. Therapeutic Strategies to Overcome ALK Resistance in Cancer. Therapeutic Strategies to Overcome ALK Resistance in Cancer 1 29 .
Yao Chen, Xiaochen Zhang, Qi Jiang, Bo Wang, Yina Wang & Yan Junrong. (2020) Lung adenocarcinoma with a novel SRBD1-ALK Fusion responding to crizotinib. Lung Cancer 146, pages 370-372.
Crossref
HuiWen Qian, Juan Li, LiRong Zou, Cheng Ji, HaiYan Li, YuShuang Zheng, LingChuan Guo, WeiDong Zhu & Yi Zhang. (2020) LTBP1-ALK: A novel fusion identified in malignant pleural effusions from a patient with advanced lung adenocarcinoma. Lung Cancer 144, pages 93-97.
Crossref
Panwen Tian, Yujie Liu, Hao Zeng, Yuan Tang, Analyn Lizaso, Junyi Ye, Lin Shao & Yalun Li. (2020) Unique molecular features and clinical outcomes in young patients with non-small cell lung cancer harboring ALK fusion genes. Journal of Cancer Research and Clinical Oncology 146:4, pages 935-944.
Crossref
Sai-Hong Ignatius Ou, Viola W. Zhu & Misako Nagasaka. (2020) Catalog of 5’ Fusion Partners in ALK-positive NSCLC Circa 2020. JTO Clinical and Research Reports 1:1, pages 100015.
Crossref
Jun Guo, Junping Shi, Ming Yao, Yi Jin, Dengxiang Liu, Weiling Liu, Kai Wang & Da Jiang. (2020) A rare double ALK fusion variant EML4-ALK and CDK15-ALK in lung adenocarcinoma and response to crizotinib. Medicine 99:45, pages e22631.
Crossref
Di Ma, Yan Zhang, Puyuan Xing, Xuezhi Hao, Mengzhao Wang, Yan Wang, Li Shan, Tao Xin, Hongge Liang, Yang Du, Zhaohui Zhang, Li Liang & Junling Li. (2019) Clinical features and outcomes of ALK rearranged non‐small cell lung cancer with primary resistance to crizotinib . Thoracic Cancer 10:5, pages 1213-1219.
Crossref
Hao Huang. (2018) Anaplastic Lymphoma Kinase (ALK) Receptor Tyrosine Kinase: A Catalytic Receptor with Many Faces. International Journal of Molecular Sciences 19:11, pages 3448.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.